Strategies will focus on public and private companies developing potentially life-changing medical treatments Partnership combines the insights and scale of BlackRock’s active investment platform with QLS’s cutting-edge approach to investing in life sciences NEW YORK, Jul. 18, 2022 (BUSINESS WIRE) -- BlackRock and QLS Advisors LLC, a life sciences technology and advisory firm, have announced a...
BIO, QLS, and Informa Pharma Intelligence have released a new report on clinical development success rates covering 2011-2020
The report includes comparisons of success rates across indications and modalities, regulatory factors, and predictive factors driving successes and failures in drug development. This new data will help shape risk profiles and valuation metrics across investment and pharma R&D portfolios. Access it here.
Partnership will help inform key decisions with new drug-level probability of approval scores powered by QLS and incorporated into Informa Pharma Intelligence’s Biomedtracker